Matthew Griffin, described as “The Adviser behind the Advisers” and a “Young Kurzweil,” is the founder and CEO of the World Futures Forum and the 311 Institute, a global Futures and Deep Futures consultancy working between the dates of 2020 to 2070, and is an award winning futurist, and author of “Codex of the Future” series. Regularly featured in the global media, including AP, BBC, Bloomberg, CNBC, Discovery, RT, Viacom, and WIRED, Matthew’s ability to identify, track, and explain the impacts of hundreds of revolutionary emerging technologies on global culture, industry and society, is unparalleled. Recognised for the past six years as one of the world’s foremost futurists, innovation and strategy experts Matthew is an international speaker who helps governments, investors, multi-nationals and regulators around the world envision, build and lead an inclusive, sustainable future. A rare talent Matthew’s recent work includes mentoring Lunar XPrize teams, re-envisioning global education and training with the G20, and helping the world’s largest organisations envision and ideate the future of their products and services, industries, and countries. Matthew's clients include three Prime Ministers and several governments, including the G7, Accenture, Aon, Bain & Co, BCG, Credit Suisse, Dell EMC, Dentons, Deloitte, E&Y, GEMS, Huawei, JPMorgan Chase, KPMG, Lego, McKinsey, PWC, Qualcomm, SAP, Samsung, Sopra Steria, T-Mobile, and many more.
WHY THIS MATTERS IN BRIEF
By combining human cells and mechanical components researchers have created a new kind of hybrid human organ that works as well as the real thing.
Love the Exponential Future? Join our XPotential Community, future proof yourself with courses from XPotential University, read about exponential tech and trends, connect, watch a keynote, or browse my blog.
Patients with kidney failure require regular dialysis which is an invasive and potentially risky treatment. But now researchers at the University of California San Francisco (UCSF) have successfully demonstrated a hybrid biological-mechanical “bio-artificial” kidney that can be implanted into patients and that works without the need for powerful and often debilitating drugs.
The kidney performs several vital functions in the body, most notably filtering toxins and waste products out of the blood, but also regulating blood pressure, electrolyte concentrations, and other bodily fluids, so when kidneys begin to fail replicating these processes is complicated. Patients often start with dialysis, but this is time consuming and un comfortable.
The Future of Healthcare 2030, by Keynote Matthew Griffin
A longer term fix is a kidney transplant which can restore a higher quality of life but comes with the risky side effect of requiring immune suppressing drugs to prevent organ rejection.
The new kidney though can be implanted into a patient to perform the main functions of the real thing, but without the need for the immune suppressing drugs or blood thinners which are also often needed when patients have kidney transplants.
The new device is made up of two main parts. The hemofilter is made up of silicon semiconductor membranes that remove waste products from blood, and the bioreactor, meanwhile, contains engineered renal tubule cells, which regulate water volume, electrolyte balance, and other metabolic functions. The membranes also protect these cells from being attacked by the patient’s immune system.
How it works
Previous tests had gotten each of these parts working independently, but this is the first time the team has tested them working in tandem in one device.
The bioartificial kidney connects to two major arteries in the patient – one that transports blood to be filtered in, and one that transports filtered blood back into the body – as well as to the bladder, where the waste products are deposited as urine.
The team has now conducted proof of concept experiments, showing that the bioartificial kidney works under blood pressure alone, without the need for pumps or external power sources. The renal tubule cells survived and continued functioning throughout the test.
For their efforts, the UCSF researchers have now been awarded a $650,000 prize from KidneyX, as one of the winners of the Phase 1 Artificial Kidney Prize.
“Our team engineered the artificial kidney to sustainably support a culture of human kidney cells without provoking an immune response,” says Shuvo Roy, lead researcher on the project. “Now that we have demonstrated the feasibility of combining the hemofilter and bioreactor, we can focus on upscaling the technology for more rigorous preclinical testing, and ultimately, clinical trials.”
The team describes the bioartificial kidney in the video above.